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Background: Disease relapse remains the most common
cause of death after allogeneic hematopoietic stem-cell
transplantation (SCT). Speciﬁcally, prevention of relapse in
transplants performed after reduced intensity conditioning
(RIC) relies on a donor derived graft-versus-tumor (GVT)
effect, which is primarily mediated by T-cells. We hypothe-
sized that a high graft T-cell dose enhances GVT and im-
proves outcomes. We therefore analyzed the impact of graft
composition on transplant outcomes in patients undergoing
allogeneic peripheral blood SCT with a uniform RIC regimen.
Methods: We studied 183 consecutive patients who under-
went a ﬁrst allogeneic SCT with peripheral blood stem-cells
and ﬂudarabine (120mg/m2) + busulfan (6.4mg/kg) condi-
tioning. Patients were allografted at the University of Penn-
sylvania between August 2006 and March 2013. Doses of
CD3, CD8, CD4 and CD34 cells in the graft were determined
by standard methods. Univariate analyses of outcomes were
performed using cumulative incidence and Cox regression
analyses. Multivariable models were constructed using the
backward elimination method, including variables with
p<0.1.
Results: The median follow-up was 20.2 mo. (range 0.4 e
78). Patients had a median age of 62 (range 21-76) and dis-
eases included AML (71), MDS (45), NHL (38), CLL (9), ALL (5)
and others (15). Mean cell doses were CD3: 2.2x108/kg (range
0.17-5.5), CD8: 0.38x108/kg (range 0.03 e 1.49), CD4:
0.96x108/kg (range 0.1 e 3.05) and CD34: 5.8x106/kg (range
1.2-21.4).
A univariate analysis of overall survival showed a trend
for improved survival in patients with high CD8 cell doses
(HR¼0.51, 95%CI [0.24,1.09], p¼0.08). The total nucleated cell
dose signiﬁcantly correlated with overall survival (HR¼0.95,
[0.90, 0.99], p¼0.04). In a multivariate model CD8 cell doses
signiﬁcantly correlated with improved survival (HR¼0.41,
[0.19, 0.91], p¼0.03).Figure 1. The impact of CD8 cell dose on RFSSimilar analyses of the relapse risk and relapse free sur-
vival revealed a signiﬁcant protective effect of high CD8 cell
doses (HR¼0.36, [0.15, 0.90], p¼0.03 and HR¼0.46, [0.23,
0.93], p¼0.03, respectively). Figure 1 illustrates the impact of
high (>0.7) and low CD8 cell doses on relapse-free survival.
Acute graft-versus-host disease (GVHD) did not correlate
with T-cell doses, but the risk for moderate-severe chronic
GVHD was higher in patients who received high CD8 cell
doses without reaching statistical signiﬁcance (HR¼3.35,
[0.93, 12.05], p¼0.06).
Conclusion: CD8 dose predicts clinical outcome in patients
undergoing peripheral blood RIC SCT. A higher CD8 cell dose
is a primary predictor of a lower relapse rate and improved
relapse-free and overall survival, while there is a possible
increase in chronic GVHD. Targeting high CD8 cell doses
should be considered in prospective trials of reduced in-
tensity conditioned SCT.
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Patients given allogeneic hematopoietic transplants (HSCT)
may develop subsequent malignant neoplasms (SMN).
Several variables have been identiﬁed but there are no data
about the incidence of this complication in individuals given
HSCT using reduced-intensity conditioning (RIC) methods.
The objective of this study is to deﬁne the incidence of SMN
in patients given HSCT using a RIC preparative regimen
conducted on an outpatient basis. Patients given HSCT in two
institutions between October 1998 and 2012 were analyzed.
Overall survival was analyzed with the Kaplan-Meier pro-
cedure. Patients alive at the closure of the study or those lost
to follow upwere censored. To appraise the SMNappearance,
those patients dead were also regarded as censored at that
moment, as well as those lost to follow up and those alive at
the closing of the study. 95% conﬁdence intervals for the
survival or failure estimate were calculated with the Green-
wood’s method. All the survival analyses were processed
with the StataCorp 2005. Stata Statistical Software: Release 9.
College Station, TX: StataCorp LP. A total of 416 allografted
patients with a Karnofsky performance index of 100% were
included in the study. All patients received PBSC allografts.
Engraftment occurred in 350 patients (84%). The condition-
ing regimen was delivered as an outpatient procedure in all
individuals. No patient was given radiotherapy nor antithy-
mocyte globulin during the conditioning. Three hundred and
sixty ﬁve patients (88%) were never admitted to the hospital,
whereas 12% were admitted because of grade III-IV aGVHD,
fever or mucositis. Median survival time was 15.7 months.
Survival at 6 months (95% CI): 66.4% (61.5- 70.8%), at
12 months: 53.3% (48.1 -58.1%), at 60 months: 30.6%
